Drug Trial Radar · NCT06335979
An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).
Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Oct 8, 2024
Primary completion
Nov 17, 2027
Study completion Nov 17, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of PIT565 in participants with SLE
Conditions
- Systemic Lupus Erythematosus, SLE
Interventions
PIT565Drug
In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)Time frame: From Study Day 1 until Study Day 180
Locations
11 sites in 6 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Mainz, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Szeged, Hungary
Novartis Investigative Site
Leiden, South Holland, Netherlands
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Santiago Compostela, A Coruna, Spain
Novartis Investigative Site
Bern, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.